Efficacy and Safety of Allogeneic platelet-rich plasma in Chronic Wound Treatment: A Meta-analysis of Randomized Controlled Trials

Abstract Background: Allogeneic platelet-rich plasma (al-PRP) is gaining attention in clinical practice for treating chronic refractory wounds, though research results remain controversial. Objective: To assess the clinical efficacy of al-PRP for chronic refractory wounds. Method: Databases including PubMed, Cochrane Library, Embase, CNKI, SinoMed, VIP, and WFPD were searched for randomized controlled trials comparing al-PRP with conventional treatments up to October 2023. Two researchers independently screened studies, extracted data, and assessed quality. Statistical analysis was conducted using RevMan 5.4. Results: Twelve studies with 717 cases were included. Meta-analysis showed al-PRP significantly improved outcomes compared to non-al-PRP treatments: increased healing rate (RR 2.72, 95% CI 1.77-4.19, p<0.00001), shortened healing time (SMD -1.03, 95% CI -1.31 to -0.75, p<0.00001), improved efficacy rate (RR 1.19, 95% CI 1.10-1.28, p<0.00001), increased wound shrinkage (MD 35.65%, 95% CI 21.65-49.64, p<0.00001), and reduced hospital stays (MD -2.62, 95% CI -4.35 to -0.90, p=0.003). Conclusion: Al-PRP is a feasible, effective, and safe biological therapy for chronic refractory wounds.